GLP-1 receptor agonists are the most talked-about drug class in 2026. Semaglutide (Ozempic for type 2 diabetes, Wegovy for chronic weight management) and tirzepatide (Mounjaro for type 2 diabetes, Zepbound for obesity) are self-administered weekly injections approved by FDA. Their retail list prices run four to five times higher than most branded specialty drugs, and most private insurance plans still apply strict prior authorization requirements for the weight-loss indications.
Because these drugs are self-administered at home, they are billed under Medicare Part D (pharmacy benefit), not Medicare Part B (medical benefit). There is no Medicare Average Sales Price published for them in the Part B drug file, and no J-code applies for routine outpatient use. Patients fill prescriptions at retail or mail-order pharmacies. Two major manufacturer programs have significantly lowered the out-of-pocket cost for commercially insured and uninsured patients, though Medicare beneficiaries face different rules.
This comparison page covers retail list prices, manufacturer direct-pay options, Medicare Part D coverage for diabetes versus obesity indications, the new Medicare GLP-1 Bridge program starting July 2026, Medicaid coverage, and patient assistance programs. For individual drug deep-dives, see the dedicated pages for Ozempic, Wegovy, Mounjaro, and Zepbound. Patients unsure whether they qualify for Medicaid or Medicare Extra Help can check the Medicaid income limits and Medicare eligibility guides.
What GLP-1 Drug Costs 2026 Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same glp-1 drug costs 2026 can cost many times more at a hospital than at your local pharmacy:
2026 GLP-1 Drug Costs 2026 Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Retail cash price (no insurance) | $935 - $1,349/month | Ozempic ~$935-$969; Mounjaro ~$1,069; Zepbound ~$1,029; Wegovy ~$1,349 |
| Manufacturer direct-pay program | $149 - $499/month | NovoCare Pharmacy: Wegovy $149-$349/mo; LillyDirect: Zepbound vials $349-$499/mo |
| Manufacturer savings card (commercial insurance) | $25/month copay | Novo Nordisk and Lilly both offer $25/month savings cards for commercially insured patients; not valid for Medicare/Medicaid |
| Medicare Part D (diabetes indication) | Varies by plan; subject to $2,100 annual OOP cap | Ozempic and Mounjaro covered for type 2 diabetes; formulary tier determines copay |
| Medicare GLP-1 Bridge (weight loss, July 2026) | $50/month flat copay | Wegovy and Zepbound KwikPen only; prior authorization required; runs July 1, 2026 through Dec 31, 2027; $50 does NOT count toward $2,100 OOP cap |
| Medicaid | $1 - $10/prescription (where covered) | Covered in most states for type 2 diabetes; obesity coverage limited to ~13 states as of early 2026 |
Retail prices are pharmacy counter list prices (WAC-based). Manufacturer program prices verified against NovoCare and LillyDirect as of May 2026. Medicare Bridge program effective July 1, 2026 per CMS announcement.
Source: NovoCare pharmacy, LillyDirect, CMS Medicare GLP-1 Bridge, GoodRx, KFF 2026
Why Hospitals Charge So Much
GLP-1 drugs like Ozempic and Mounjaro are occasionally administered in clinical settings (for dose initiation or monitoring), and in those cases hospitals apply facility markups on top of their acquisition cost. Because no dedicated HCPCS J-code exists for semaglutide or tirzepatide in routine use, hospitals billing them as infusion or injection services typically use J3490 (unclassified drug). That unclassified code gives less pricing transparency than dedicated J-codes, making it harder to benchmark the charge against a published Medicare rate.
For the vast majority of patients, however, these drugs are filled at retail or mail-order pharmacies and billed through the pharmacy benefit (Part D), not the medical benefit. A high line-item charge on a hospital bill for J3490 semaglutide or tirzepatide is rare and typically signals the drug was given as part of an inpatient procedure or clinical observation stay, not as a routine outpatient fill. If you see such a charge, compare the billed amount against the manufacturer's published WAC price and the usual Part D formulary cost as a reference point.
The larger cost surprise with GLP-1 drugs is not inpatient billing but sticker shock at the pharmacy counter when insurance denies coverage. List prices for these drugs are set at $935 to $1,349 per month, but manufacturer self-pay programs, savings cards, and the new Medicare Bridge program all exist specifically to reduce that gap. Patients who are denied coverage for a weight-loss indication should ask their prescriber about the manufacturer direct pharmacy options, which do not require insurance approval.
Patient Assistance Programs
Novo Nordisk (maker of Ozempic and Wegovy) and Eli Lilly (maker of Mounjaro and Zepbound) both run savings programs for commercially insured patients and direct self-pay options for uninsured patients. Note that neither manufacturer's PAP currently covers Wegovy or Zepbound for weight-loss use for low-income patients the same way other drug PAPs do (free supply programs). The primary programs available in 2026 are:
Patient assistance programs for GLP-1 Drug Costs 2026| Manufacturer program | Cost / Benefit | How to apply |
|---|
| NovoCare Savings Card (Ozempic/Wegovy) | $25/month with commercial insurance; max $100/month savings | novocare.com |
| NovoCare Direct Pharmacy (self-pay Wegovy) | $149/month for 1.5 mg and 4 mg doses; $349/month for standard doses | novocare.com/pharmacy |
| Lilly Savings Card (Zepbound/Mounjaro) | $25/month with commercial insurance; up to $1,300/year savings | zepbound.lilly.com/savings |
| LillyDirect Self-Pay (Zepbound vials) | $349 - $499/month for Zepbound single-dose vials without insurance | lillydirect.com |
| Novo Nordisk PAP (Ozempic for diabetes, income-based) | Free Ozempic for Medicare/no-insurance patients; income at or below 200% FPL | novocare.com |
Savings cards are not valid for Medicare or Medicaid beneficiaries. PAP eligibility for Ozempic requires Medicare or no insurance, income at or below 200% FPL, and no Medicaid/LIS enrollment. Wegovy is not currently in Novo Nordisk's free supply PAP. Lilly Cares does not currently include Zepbound.
Source: NovoCare.com, LillyDirect.com, Zepbound.lilly.com/savings, NeedyMeds.org 2026
Medicare Part D
Medicare Part D coverage for GLP-1 drugs depends on the indication. Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg) and Mounjaro (tirzepatide) are covered by most Part D plans when prescribed for type 2 diabetes, subject to prior authorization and formulary tier. The out-of-pocket cost is plan-specific but falls under the 2026 annual Part D OOP cap of $2,100.
For weight-loss indications, federal law historically barred Medicare Part D from covering drugs prescribed solely for weight loss. That changes partially starting July 1, 2026 with the Medicare GLP-1 Bridge program. Under the Bridge, eligible Medicare Part D beneficiaries can access Wegovy (all formulations), Zepbound KwikPen, or Foundayo for a flat $50 monthly copay through December 31, 2027. The $50 copay does NOT count toward your annual $2,100 OOP cap, and Extra Help (Low Income Subsidy) cannot be used for Bridge-covered drugs. Prior authorization from your physician is required.
Beginning January 2027, the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) is scheduled to replace the Bridge with a more permanent five-year program running through 2031. Patients already enrolled in the Bridge program should check with their Part D plan about continuity of coverage.
Common GLP-1 Drug Costs 2026 Billing Errors
GLP-1 drugs generate billing disputes primarily at the pharmacy benefit level. Common issues include:
- Insurance denies weight-loss (obesity) claim but would cover the same drug for type 2 diabetes -- check whether your diagnosis code on the prescription says E11 (type 2 diabetes) rather than obesity
- Savings card not applied by pharmacist -- if you have commercial insurance and presented a Lilly or Novo Nordisk savings card, confirm the $25 copay was applied before paying
- Wrong product billed -- Mounjaro (diabetes) and Zepbound (obesity) are the same molecule (tirzepatide) in different labeling; similarly Ozempic (diabetes) and Wegovy (obesity) are both semaglutide. Coverage differs by indication so wrong product coding changes coverage
- Medicare Bridge program $50 copay incorrectly counted toward annual deductible or OOP cap -- the $50 Bridge copay specifically does not count toward the $2,100 Part D OOP cap or deductible
- Extra Help subsidy applied to a Bridge drug -- Extra Help cannot be used for drugs obtained through the Medicare GLP-1 Bridge program; if this is applied by error it may trigger a claim correction
Frequently Asked Questions
What is the cheapest way to get Ozempic or Wegovy in 2026?
For commercially insured patients, the Novo Nordisk savings card cuts your copay to $25 per month. For uninsured patients, NovoCare Direct Pharmacy offers Wegovy at $149 per month for the 1.5 mg and 4 mg doses, and $349 per month for standard doses. The GoodRx retail cash price is approximately $935 to $969 per month for Ozempic without any program. Medicare beneficiaries should check if they qualify for the new Medicare GLP-1 Bridge program at $50 per month starting July 1, 2026.
How does Mounjaro differ from Zepbound?
Mounjaro and Zepbound contain the same active ingredient, tirzepatide, made by Eli Lilly. The difference is FDA approval: Mounjaro is approved for type 2 diabetes management, while Zepbound is approved for chronic weight management in adults with obesity (BMI 30 or higher) or overweight with a weight-related condition (BMI 27 or higher). Insurance plans treat them differently -- Mounjaro qualifies for diabetes coverage while Zepbound requires specific obesity coverage, which many plans restrict or exclude.
Does Medicare cover Wegovy or Zepbound for weight loss in 2026?
Starting July 1, 2026, yes, through a temporary program called the Medicare GLP-1 Bridge. Eligible Medicare Part D beneficiaries can get Wegovy (all forms), Zepbound KwikPen, or Foundayo at a flat $50 per month copay through December 31, 2027. You need prior authorization from your doctor. The $50 copay does not count toward your annual $2,100 Part D OOP cap. Extra Help (Low Income Subsidy) cannot be used for Bridge-covered drugs.
What is the difference between Ozempic and Wegovy?
Both contain semaglutide (the same active ingredient) made by Novo Nordisk. Ozempic (0.5 mg, 1 mg, 2 mg weekly injections) is approved for type 2 diabetes and cardiovascular risk reduction. Wegovy (0.25 mg up to 2.4 mg weekly injections) is approved for chronic weight management. Wegovy uses higher doses and has a different FDA approval. Medicare and most insurers have different coverage rules for each, which is why the same semaglutide can be covered for one use and not another.
Can I get GLP-1 drugs through Medicaid?
Coverage varies by state. As of early 2026, most state Medicaid programs cover Ozempic and Mounjaro when prescribed for type 2 diabetes. Coverage for obesity treatment (Wegovy, Zepbound) is much more limited -- only about 13 states cover GLP-1s for obesity under their Medicaid programs. The federal BALANCE Model starting in 2026 aims to expand Medicaid obesity drug coverage, but not all states are participating. Check your state Medicaid agency for current formulary coverage.
Why are GLP-1 drugs so expensive in the US?
GLP-1 drugs are set at list prices of $935 to $1,349 per month by their manufacturers. The US does not regulate pharmaceutical list prices, and these drugs have no generic competition as of 2026. Novo Nordisk and Eli Lilly set prices based on the value they deliver in diabetes control and weight reduction. International prices are far lower -- Ozempic costs around $100 to $200 per month in Canada. Compounded semaglutide has been available from specialty compounding pharmacies, though FDA enforcement actions against unauthorized compounders began in 2025.
What is the Medicare GLP-1 Bridge program and who qualifies?
The Medicare GLP-1 Bridge is a CMS program running July 1, 2026 through December 31, 2027. It provides Wegovy, Zepbound KwikPen, and Foundayo at a $50 monthly copay to eligible Medicare Part D beneficiaries. To qualify, you must have Medicare Part D coverage, meet BMI criteria (BMI 30 or higher, or BMI 27 or higher with a qualifying health condition such as heart disease or prediabetes), and receive prior authorization. The $50 copay does not count toward the annual $2,100 Part D OOP cap, and Extra Help cannot be applied to Bridge drugs.
Are GLP-1 savings cards valid for Medicare patients?
No. Manufacturer savings cards from Novo Nordisk and Eli Lilly are not valid for Medicare, Medicaid, or any other federal healthcare program beneficiaries. This is a federal anti-kickback statute requirement. Medicare patients need to use Medicare Part D coverage (for diabetes indications), the new $50/month Medicare GLP-1 Bridge program (for weight loss, starting July 2026), or the manufacturer's PAP programs for uninsured patients that have specific Medicare rules.
